Clinical Trial Update: Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial comparing azacitidine plus erythropoietin versus azacitidine alone in low-risk myelodysplastic syndromes; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Erythropoietin (erythropoietin)

Snippet

Sponsor: Larry Cripe, MD | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2017-05-31